We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Implementation in action: Collaborating on the transition to primary HPV screening for cervical cancer in the United States.
- Authors
Downs, Levi S.; Nayar, Ritu; Gerndt, Jane; Saslow, Debbie; Arrindell, Deborah; Feldman, Sarah; Franco, Eduardo L.; García, Francisco; Lind, Eileen; Lorey, Thomas S.; MacLaughlin, Kathy L.; Marcus, Jenna Z.; Novetsky, Akiva P.; Perkins, Rebecca B.; Saraiya, Mona; Satterfield, Lisa; Smith, Robert A.; Waxman, Alan G.; Wentzensen, Nicolas
- Abstract
Therefore, changing screening practices from cytology alone to primary HPV screening is essential and may have a different set of challenges than the transition faced by programs performing cotesting, such as access and cost considerations. For a successful transition to the widespread use of primary HPV screening, the I Insurance Coverage/Payors Workgroup i is providing support for billing and coding for primary HPV screening. Keywords: cervical neoplasms; cytopathology or cytotechnology; gynecologic oncology; obstetrics and gynecology; prevention EN cervical neoplasms cytopathology or cytotechnology gynecologic oncology obstetrics and gynecology prevention 458 460 3 09/06/23 20230901 NES 230901 In July 2020, the American Cancer Society (ACS) released an updated cervical cancer screening guideline calling for primary human papillomavirus (HPV) screening as the preferred strategy.[1] I Primary HPV screening i refers to cervical cancer screening with an HPV test alone as the initial screening modality.
- Subjects
HUMAN papillomavirus; CERVICAL cancer; EARLY detection of cancer; CLINICAL decision support systems; GYNECOLOGIC cancer; MEDICAL personnel; SAFETY-net health care providers
- Publication
CA: A Cancer Journal for Clinicians, 2023, Vol 73, Issue 5, p458
- ISSN
0007-9235
- Publication type
Article
- DOI
10.3322/caac.21786